Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients

Abstract

Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.

Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients

“…6 Also, there has been a previous trial showing high response rates with DRV/r and ETV, and recent studies showing rates close to 100% in salvage therapy of patients treated with a combination of three new drugs, from different classes. [10][11][12] In Brazil, three previous studies evaluated the effectiveness of DRV/r-based salvage regimens for highly experienced patients and found similar results after 48 weeks. Vidal et al prospectively followed 92 patients who received a DRV/r-based ARV salvage regimen, and reported 83% virological suppression rate.…”

Non-AIDS Morbidity among HIV Patients

“…Similarly, ETV + OBR provided better virological suppression and improved immunological response than the optimized background regimen alone after 96 weeks (248). In people with multidrugresistant HIV who have few remaining treatment options, the combination of RAL, ETV and DRV/r was well tolerated and was associated with a rate of virological suppression similar to that expected among treatment-naive people (249,250).…”

La gravité de l'infection par le VIH

“…Etravirine, raltegravir et darunavir, utilisés en combinaison, se sont avérés efficaces même en cas de résistances multiples. Les patients n on traitables ont presque disparu de n os consultations [8].…”